BioAge Labs Statistics
Total Valuation
BioAge Labs has a market cap or net worth of $255.07 million. The enterprise value is -$94.52 million.
| Market Cap | 255.07M |
| Enterprise Value | -94.52M |
Important Dates
The last earnings date was Thursday, November 5, 2026, after market close.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioAge Labs has 45.96 million shares outstanding. The number of shares has increased by 18.03% in one year.
| Current Share Class | 45.96M |
| Shares Outstanding | 45.96M |
| Shares Change (YoY) | +18.03% |
| Shares Change (QoQ) | +2.39% |
| Owned by Insiders (%) | 2.36% |
| Owned by Institutions (%) | 80.44% |
| Float | 39.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 29.66 |
| Forward PS | 146.29 |
| PB Ratio | 0.74 |
| P/TBV Ratio | 0.74 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.51, with a Debt / Equity ratio of 0.01.
| Current Ratio | 15.51 |
| Quick Ratio | 15.06 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -913.20 |
Financial Efficiency
Return on equity (ROE) is -34.56% and return on invested capital (ROIC) is -23.77%.
| Return on Equity (ROE) | -34.56% |
| Return on Assets (ROA) | -22.40% |
| Return on Invested Capital (ROIC) | -23.77% |
| Return on Capital Employed (ROCE) | -34.58% |
| Weighted Average Cost of Capital (WACC) | 10.71% |
| Revenue Per Employee | $138,694 |
| Profits Per Employee | -$1.74M |
| Employee Count | 62 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.71% in the last 52 weeks. The beta is 1.19, so BioAge Labs's price volatility has been higher than the market average.
| Beta (5Y) | 1.19 |
| 52-Week Price Change | -30.71% |
| 50-Day Moving Average | 6.60 |
| 200-Day Moving Average | 15.12 |
| Relative Strength Index (RSI) | 41.92 |
| Average Volume (20 Days) | 743,902 |
Short Selling Information
The latest short interest is 3.73 million, so 8.11% of the outstanding shares have been sold short.
| Short Interest | 3.73M |
| Short Previous Month | 3.43M |
| Short % of Shares Out | 8.11% |
| Short % of Float | 9.49% |
| Short Ratio (days to cover) | 4.13 |
Income Statement
In the last 12 months, BioAge Labs had revenue of $8.60 million and -$107.80 million in losses. Loss per share was -$2.54.
| Revenue | 8.60M |
| Gross Profit | -90.91M |
| Operating Income | -120.54M |
| Pretax Income | -107.80M |
| Net Income | -107.80M |
| EBITDA | -120.26M |
| EBIT | -120.54M |
| Loss Per Share | -$2.54 |
Balance Sheet
The company has $352.32 million in cash and investments and $2.73 million in debt, with a net cash position of $349.59 million or $7.61 per share.
| Cash & Investments | 352.32M |
| Total Debt | 2.73M |
| Net Cash | 349.59M |
| Net Cash Per Share | $7.61 |
| Equity (Book Value) | 346.45M |
| Book Value Per Share | 7.54 |
| Working Capital | 276.03M |
Cash Flow
In the last 12 months, operating cash flow was -$102.52 million and capital expenditures -$484,000, giving a free cash flow of -$103.00 million.
| Operating Cash Flow | -102.52M |
| Capital Expenditures | -484,000 |
| Depreciation & Amortization | 282,000 |
| Net Borrowing | -3.50M |
| Free Cash Flow | -103.00M |
| FCF Per Share | -$2.24 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,401.81% |
| Pretax Margin | -1,253.60% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioAge Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -18.03% |
| Shareholder Yield | -18.03% |
| Earnings Yield | -45.85% |
| FCF Yield | -40.38% |
Analyst Forecast
The average price target for BioAge Labs is $28.89, which is 420.54% higher than the current price. The consensus rating is "Buy".
| Price Target | $28.89 |
| Price Target Difference | 420.54% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | -29.70% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioAge Labs has an Altman Z-Score of 16.08 and a Piotroski F-Score of 4.
| Altman Z-Score | 16.08 |
| Piotroski F-Score | 4 |